Abstract: The ACC/AHA 2013 guideline recommends high-intensity statin therapy for a decrease in low-density lipoprotein cholesterol (LDL-C) level by >50% among patients with baseline values of ≥190 mg/dL (approximately 4.872 mmol/L); however, this value should be modified before applying it to Korean populations. We investigated the statin-specific LDL-C-lowering effects in Korean patients with baseline LDL-C value ≥4.872 mmol/L. Data of patients prescribed a statin for the first time from January 2009 to December 2013 were assessed. In patients with baseline LDL-C value ≥4.872 mmol/L, laboratory data for a maximum of 6 months from the date of first statin prescription were collected. Among 33,721 patients who were prescribed a statin for the first time, 655 patients had a baseline LDL-C value ≥4.872 mmol/L (1.9%). Of these, 179 patients were analysed. Patients receiving moderate-intensity statins were divided into two groups based on LDL-C reduction rate (p = 0.0002), defined as moderate-high-intensity (atorvastatin 20 mg, rosuvastatin 10 mg, simvastatin 20 mg) and moderate-low-intensity (atorvastatin 10 mg, pitavastatin 2 mg, pravastatin 40 mg) statin groups. LDL-C reduction rates did not significantly differ between the moderate-high-and high-intensity statin groups (p = 0.4895). We found that some moderate-intensity statins demonstrated a LDL-Clowering effect of more than 50% in Korean patients with a baseline LDL-C value ≥4.872 mmol/L. Our results reflect the need of a large-scale, randomized, controlled trial on partial reclassification of statins for patients with baseline LDL-C value ≥4.872 mmol/L before adopting ACC/AHC guidelines in Korea.
There had been no major changes in hypercholesterolaemia treatment guidelines for nearly a decade since the National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III guideline was published in 2004 [1] , until the American College of Cardiology-American Heart Association (ACC/ AHA) presented a new guideline for the treatment of blood cholesterol in 2013 [2] .
The ACC/AHA guideline is very different from the NCEP-ATP III guideline in that it does not set a target value for low-density lipoprotein cholesterol (LDL-C) [2] , but rather recommends that physicians actively administer a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor (HMG-CoA reductase inhibitor, statin) classified according to LDL-C-lowering effects. This new ACC/AHA guideline emphasizes early statin treatment in order to prevent cardiovascular diseases in highrisk patients. In particular, it recommends high-intensity statin therapies to decrease LDL-C by more than 50% in patients with 190 mg/dL (approximately 4.872 mmol/L) or higher baseline LDL-C [2] . However, it is uncommon for Asians including Koreans to have a LDL-C level above 4.872 mmol/L.
In addition, in comparison with Western populations, extensive research in Asian populations has indicated an effect of comparably low-dosage statins on cardiovascular disease prevention [3] [4] [5] [6] [7] . Each country has a different racial composition and cultural environment, and the new ACC/AHC guideline must be carefully considered before applying it to patients in Korea and other Asian countries without modifications.
Many types of statins with different LDL-C-lowering effects are available, and many studies on the LDL-C-lowering effects of statins have been published [8] [9] [10] [11] [12] [13] [14] [15] . However, there have been no reports on statin-specific LDL-C-lowering effects in Asian patients with LDL-C ≥ 4.872 mmol/L, and additional research is needed in order to determine whether to maintain the NCEP-ATP III guideline or adopt the new ACC/AHC guideline. For this purpose, this study aimed to investigate the LDL-C-lowering effects of specific statins in patients with a baseline LDL-C level over 4.872 mmol/L prior to statin prescription in Korea, so as to provide baseline data for future research.
Methods

Patient medications.
This retrospective cohort study included patients who were prescribed a statin medication for the first time based on electronic medical records (EMR). Seven types of statins currently available in Korea were selected for this study, and those medications were classified into 20 categories according to their dosages: atorvastatin (10, 20, 40 and 80 mg), fluvastatin (40 and 80 mg), pitavastatin (2 and 4 mg), pravastatin (10, 20 and 40 mg), rosuvastatin (5, 10, 20 and 40 mg), simvastatin (10, 20 and 40 mg) and simvastatin plus ezetimibe (10/10 and 20/10 mg). Other drug combinations (atorvastatin plus amlodipine or pravastatin plus fenofibrate) were excluded.
Extraction of the study sample. This two-centre, EMR-based study was conducted at Seoul St. Mary's Hospital and Seoul National University Hospital in Korea. We established the study dataset including prescription and laboratory data based on a Clinical Data Warehouse (CDW) system, which is a database optimized for mass storage and complex query processing for clinical research. It also provides comprehensive views of clinical data for specific purposes. A CDW provides numerous benefits to researchers for efficient access to patient information and links to multiple operational data sources. We developed a research database from a subset of the data based on the study protocol.
Extraction of the study sample. The subjects were outpatients at the Seoul St. Mary's Hospital and Seoul National University Hospital from January 2009 to December 2013. Among these patients, data for those who were prescribed a statin for the first time during this period were extracted. Patients prescribed a statin for the first time were defined as those who had not been prescribed a statin within the previous 6 months. Patients who met this definition with a baseline LDL-C of 4.872 mmol/L or higher were extracted separately and laboratory data for a maximum of 6 months from the date of their first statin prescription were collected. The date a patient was prescribed a statin was considered the baseline, and their next visit within 2-4 months (mean 3 months) was referred to as visit 1. Laboratory data were also extracted at baseline and visit 1 for the assessment of total cholesterol, triglyceride, LDL-C and high-density lipoprotein cholesterol.
Assumption of drug compliance. In order to confirm whether patients were compliant with their prescribed dosages, their next visits were predicted based on the number of days of their first statin prescription. Patients who visited later than the day their prescription was expected to run out were presumed to have not fully adhered to their prescribed dosage and were therefore excluded from the study.
Privacy protection.
All extracted data files and patient numbers were encrypted, and study investigators could not determine the actual patient number in order to prevent patient identification through EMR data. This study did not use any private patient information or possess any possibility of additional physical risks to the patients involved. This study was approved by the Institutional Review Boards of the Catholic University of Korea and the Seoul National University Hospital. Owing to the anonymity of the data and the retrospective nature of the study, informed consent was not required.
Statistical analysis.
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). For descriptive statistics, mean AE standard deviations are reported. The statistical tests were performed for groups with more than 10 cases. We used ANOVA (analysis of variance) to test LDL-C reduction rate. We compared those values to evaluate the statin effect. R package (version 3.1.2) is used for drawing boxplots to show the difference between statin groups.
Results
Baseline LDL-C levels were available for a total 33,721 patients who were prescribed a statin from January 2009 to December 2013 ( fig. 1 ). Among them, 655 patients had a baseline LDL-C of 4.872 mmol/L or higher (655/33,721, 1.9%). We excluded 459 patients with no LDL-C data on visit 1, 10 patients considered to have low compliance, and seven patients with missing data or duplicate prescriptions. Ultimately, 179 patients were included in this study.
Statin prescriptions of seven types and 18 varieties were extracted (Table 1) . Fourteen patients (14/179, 7.8%) were prescribed high-intensity statin therapy. The mean age of first statin prescription was 60 AE 11 years, and 35.2% (63/179) of patients were ≥65 years old. The average time between the date of prescription and visit 1 was 93 AE 13 days. The mean BMI was 24.8 AE 3.5 kg/m 2 , and mean baseline LDL-C was 5.4 AE 0.8 mmol/L. High-intensity atorvastatin (40 mg) had a LDL-C reduction rate of 47% (from 5.6 AE 0.9 mmol/L to 3.0 AE 1.7 mmol/L), while rosuvastatin (20 mg) had a LDL-C reduction rate of 58% (from 5.8 AE 1.3 mmol/L to 2.4 AE 0.6 mmol/L) ( Table 2 ). The LDL-C reduction rates for atorvastatin (20 mg), pitavastatin (4 mg), simvastatin (20 and 40 mg) and rosuvastatin (10 mg), which are moderate-intensity statins, were all approximately 50%. However, the sizes of these groups are relatively small, and the data cannot be considered statistically significant.
In the present study, the statin treatment groups with ≥10 patients were only associated with moderate-intensity statins. These six statins were further divided two groups according to the LDL-C reduction rate -the moderate-high-and moderatelow-intensity statin groups ( fig. 2 ). The moderate-high-intensity group included atorvastatin (20 mg), simvastatin (10 mg) and rosuvastatin (10 mg) and showed a 50% reduction rate; furthermore, the moderate-low-intensity group included atorvastatin (10 mg), pitavastatin (2 mg) and pravastatin (40 mg) and showed an approximately 40% reduction rate. Within the groups of atorvastatin (10 mg), pitavastatin (2 mg) and pravastatin (40 mg), the average change in the reduction rate (in per cent) was not significant (p = 0.8167). Moreover, within the groups of rosuvastatin (10 mg), simvastatin (20 mg) and atorvastatin (20 mg), the average change in the reduction rate (in per cent) was not significant (p = 0.9632). However, a significant difference was noted in LDL-C reduction between the moderate-high-and moderate-low-intensity statin groups (p = 0.0002).
The sample sizes in the fluvastatin (80 mg), pitavastatin (4 mg), rosuvastatin (5 mg) and simvastatin (40 mg) groups were not sufficiently large to be classified as either "moderate-high" or "moderate-low." After excluding these groups, the LDL-C reduction rate of moderate-intensity statins in the other six groups was compared with that of the high-intensity statin and low-intensity statin groups ( fig. 3) . The LDL-C reduction rates for moderate-high-and high-intensity statins were 51 AE 16% and 53 AE 22%, respectively, which were not significantly different (p = 0.4895). Similarly, the LDL-C reduction rates for moderate-low-and low-intensity statins were 39 AE 19% and 43 AE 16%, respectively, which were not significantly different (p = 0.4349).
Discussion
The new 2013 ACC/AHA guideline [2] aims for atherosclerotic cardiovascular disease (ASCVD) prevention as a major goal and no longer applies the existing target LDL-C values. This new guideline specifies that active statin treatment at an earlier stage can be an important factor in lowering the risk of developing ASCVD and recommends high-intensity or moderate-intensity statin treatments for the statin-benefit group, which is divided into several subgroups. It also excludes LDL-C targets and instead suggests a LDL-C lowering rate [2] . Therefore, it is not necessary to change statins or adjust dosages according to LDL-C levels. High-intensity statin therapy is defined as lowering LDL-C by approximately 50% and moderate-intensity statin therapy targets LDL-C decrease by 30-50%.
The new ACC/AHC guideline recommends that patients with a baseline LDL-C of 4.872 mmol/L and above receive high-intensity statin therapy such as atorvastatin (40-80 mg) or rosuvastatin (20-40 mg) [2] . However, in our study, the prescription frequency rate of high-intensity statin therapy was not very high (14/179, 7.8%). Among the statins that are identified as moderate-intensity by the ACC/AHA guideline, atorvastatin (20 mg), pitavastatin (4 mg), simvastatin (10 and 20 mg) and rosuvastatin (10 mg) all demonstrated LDL-C reduction rates of more than 50%, suggesting that it is advisable to establish modifications to the guideline. However, these findings are limited because the sample sizes were relatively small, making it difficult to directly compare moderateintensity and high-intensity therapies. However, the LDL-C reduction rates for the moderate-high-intensity group and the high-intensity group did not show significant differences (p = 0.4895), whereas those for the moderate-low-intensity group and low-intensity group also did not show significant differences (p = 0.4349). According to the ACC/AHC Patients' baseline characteristics and biochemical parameters, reported by statin type. Women, n (%)
19 (53) 10 (59) 4 (80) 4 (100) 1 (100) 1 (100) 15 (88) 1 (100) 3 (60) 12 (86) 0 (0) 69 (24) 9 (89) 2 (40) 9 (69) 1 ( 6 (17) 4 (44) 2 (40) 6 (46) 1 (33) 1 (20) 2 (29) Height (cm) guideline, statins are classified into three groups based on the different LDL-C reduction rates; however, based on the results of the present study, they can be divided into two groups in Korea (p < 0.001). Thus, it may be beneficial for some statins in the moderate-intensity group to be reclassified as highintensity statins. Moreover, there are many possible risks in the early application of high-intensity statin therapy for Asian patients, even those with 4.872 mmol/L or higher LDL-C, as the new guideline indicates [2] . In fact, some Asian countries such as China and Japan recommend low statin dosages due to the high occurrence rate of adverse effects, and applying the ACC/ AHA guideline will increase prescriptions for high-intensity statins and prescribed statin dosages, which can lead to more adverse effects [16, 17] . Therefore, it has been widely predicted that there will be ongoing controversies around this guideline in the future [16, 18, 19] . In this regard, it is imperative to recategorize LDL-C-lowering effects in order to apply the new guideline in Asia.
Thus, unlike the ACC/AHA guideline, this study suggests the division of moderate-intensity statins into two groups for patients with 4.872 mmol/L or higher baseline LDL-C levels.
Some moderate-intensity statins can be considered high-intensity statins, and therefore, these moderate-high-intensity statins can replace high-intensity statins in Korean patients. Therefore, replacing a high-intensity statin treatment with a moderate-high one is expected to be possible for Korean patients.
The new ACC/AHC guideline is a score based on calculations in non-Hispanic white and African American populations. In Asia, many studies have reported the preventive effect of low statin dosages on cardiovascular diseases [3] [4] [5] [6] [7] 20] . The MEGA study conducted in Japan reported that low-intensity statins, which have a much lower intensity than those used in the west, were effective to lower coronary artery disease occurrence and mortality [3] . This study further demonstrates that statins can also prevent coronary artery diseases in Asian populations whose cardiovascular disease occurrence and mortality rate are comparably low, implying that the effect of statins is race sensitive [21, 22, 23] . As a result of analysing many studies on Japanese patients, Japan has a unique system to categorize statins as low intensity and moderate intensity [21] , which differs from those of the ACC/ AHA guideline. However, Korea has been following the NCEP-ATP III guideline, and does not have any ASCVD risk scoring system of its own. Therefore, applying the suggestions of the new ACC/AHA guidelines thus far, as well as the defined intensities of statins, has been challenging in Asian patients including Korean patients. Our study has some limitations. Firstly, data were collected within a short period of time (3 months), and the LDL-Clowering effect was calculated using relatively small sample sizes. However, this time frame is in line with the new ACC/ AHC guideline, which suggests a 1-month or 3-month term after LDL-C examination in order to confirm the therapeutic response and adherence after prescribing patients a statin. Secondly, this study is a retrospective cohort study using EMR data, for which unknown confounding factors are the greatest limitation [24] . Therefore, this study was conducted with an attempt to build a standardized research plan from the beginning in order to minimize these confounding factors. We tried to control variables such as compliance to prescriptions and duplicate prescriptions, but patient compliance to the medication cannot be fully confirmed. However, we did exclude patients with predicted low compliance based on the dates of statin prescription and follow-up visit. Finally, some statin groups had very small sample sizes, which created difficulties in assessing the data. For example, the reliability of the observed 60% LDL-C-lowering effects with simvastatin (10 mg) and only 13% LDL-C-lowering effects with fluvastatin (80 mg) is questionable. For this reason, many sample groups were eliminated during analysis in order to minimize the effect of confounding factors.
In conclusion, we found that some moderate-intensity statins demonstrated a LDL-C-lowering effect of more than 50% in Korean patients with a baseline LDL-C of ≥4.872 mmol/L. However, further research regarding the effect of different statins on the prevention of cardiovascular disease is needed. Compared to the Western population, Asian individuals show lower prevalence rates of cardiovascular disease. Furthermore, high-intensity statin treatment is an untested method in Asian patients, and a review of clinical studies involving Asian patients is needed. With regard to the ACC/AHA guideline, many statin groups appear to warrant reclassification in Korea and the effects of various types and dosages of statins should be reviewed in detail. Moreover, it is very important to consider not only the LDL-C-lowering effect but also the preventive effect on cardiovascular disease when choosing a statin medication. Hence, a large-scale randomized controlled trial on this subject is necessary. 
